Big pharma giant Pfizer doubled down on the failed U.S. pharma drug I'm looking for a way to save its experimental drug Sigvotatug Vedotin — even though a key clinical trial failed to show survival benefits in patients with advanced, inoperable lung cancer, Bloomberg reports. Pfizer acquired the drug through its $43 billion purchase of Seagen, betting on a new class of therapies designed to deliver powerful cancer-preventing compounds directly to tumors. Now, the drugmaker is looking for ways to make that investment pay off. 👉 Patients who received less chemotherapy before taking the drug lived for two months longer than others - perhaps because of stronger immune systems, Jeff Danos, Pfizer's chief oncology officer, argued at a medical oncology conference. The company is currently testing its drug alongside Mark's cancer drug in Keytruda in a phase 3 trial involving patients with non-small cell lung cancer, hoping that a combination will be more effective. Chat | @geopolitics prime.

Big pharma giant Pfizer doubled down on the failed U.S. pharma drug I'm looking for a way to save its experimental drug Sigvotatug Vedotin — even though a key clinical trial failed to show survival benefits in patients with advanced, inoperable lung cancer, Bloomberg reports. Pfizer acquired the drug through its $43 billion purchase of Seagen, betting on a new class of therapies designed to deliver powerful cancer-preventing compounds directly to tumors. Now, the drugmaker is looking for ways to make that investment pay off. 👉 Patients who received less chemotherapy before taking the drug lived for two months longer than others - perhaps because of stronger immune systems, Jeff Danos, Pfizer's chief oncology officer, argued at a medical oncology conference. The company is currently testing its drug alongside Mark's cancer drug in Keytruda in a phase 3 trial involving patients with non-small cell lung cancer, hoping that a combination will be more effective. Chat | @geopolitics prime.